Health Canada granted approval for Imbruvica (ibrutinib), as an oral, once-daily, single-agent therapy for the treatment of patients with Waldenström’s macroglobulinemia. This approval was based on an investigator-led, multicenter, prospective, single-arm study in 63 patients who had received at least one prior therapy. The results of the study were published in the New England Journal...
Up to 80% of adolescents and young adults with cancer are affected by reduced fertility after treatment—but only 50% received oncofertility counseling and preservation options prior to beginning treatment.
